Abstract 4553
Background
Osimertinib was approved as a standard therapy for EGFR-mutant lung cancer with brain metastasis. It has been demonstrated that TP53 mutations was responsible for Gefitinib resistance in a preclinical study. This study was to analyze the impact of TP53 mutations on response to first-line Osimertinib in EGFR-mutant patients with brain metastasis from non-small cell lung cancer (NSCLC).
Methods
100 EGFR-mutated NSCLC patients with brain metastasis receiving first-line Osimertinib were analyzed. TP53 mutations were evaluated in all patients in relation to disease control rate (DCR), progression-free survival (PFS), and overall survival (OS).
Results
TP53 mutations were observed in 48 (48%), 11 (22.92%), 7 (14.58%), 12 (25%) and 18 (37.5%) patients in exon 5, 6, 7, and 8, respectively. TP53 mutations were significantly associated with increasing brain-metastatic sites (P < 0.05). DCR was 29.17% in TP53-mutated patients compared to 94.23% in patients with TP53-wild type (P < 0.05). All patients with TP53 exon 8 mutations had primary resistance to Osimertinib. Compared with others, significantly shorter median PFS and OS were observed both in total TP53-mutated patients (mPFS 4.8 vs 10 months, P < 0.001; mOS 10.98 vs 25.45 months, P < 0.001) and patients with TP53 exon 8 mutations ((mPFS 4 vs 9 months, P < 0.001; mOS 8.25 vs 19.98 months, P < 0.001)), compared with others. TP53 exon 8 mutation was an independent prognostic factor adjusting for other subtypes of TP53 mutation (P < 0.001).
Conclusions
TP53 mutations, especially exon 8 mutations, reduced the efficacy of Osimertinib and worsen prognosis in EGFR-mutated NSCLC patients with brain metastasis. TP53 mutation might be used as a predictor for Osimertinib therapy and a prognostic factor for EGFR-mutated NSCLC patients with brain metastasis.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Yanqiu Zhao.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3309 - Heat Shock Protein 90 chaperones and Protein Kinase D3 regulates androgen-independent prostate cancer development
Presenter: Attila Varga
Session: Poster Display session 1
Resources:
Abstract
3441 - The SWI/SNF driven reprograming for the AR cistrome is NSD2 dependent
Presenter: Katia Ruggero
Session: Poster Display session 1
Resources:
Abstract
1659 - IGF1R inhibition affects the survival of HT29 cancer cells by alterations of the TLR9- and autophagy signaling
Presenter: Györgyi Műzes
Session: Poster Display session 1
Resources:
Abstract
1379 - Characterization of atypical dMMR (deficient MisMatch Repair) tumors: a study from a large cohort of 4948 cases
Presenter: Marion Jaffrelot
Session: Poster Display session 1
Resources:
Abstract
1657 - Modulation of TLR9-dependent autophagy response via inhibition of c-Met signaling influences the survival of HT29 cancer cells
Presenter: Ferenc Sipos
Session: Poster Display session 1
Resources:
Abstract
3045 - Positive Feedback Activation of Notch Signal by Obesity Enhances Colorectal Tumorigenicity
Presenter: Dake Chu
Session: Poster Display session 1
Resources:
Abstract
2285 - The Pathological and Functional Roles of BRPF1 in Hepatocellular Carcinoma
Presenter: Lai Hung Carol Cheng
Session: Poster Display session 1
Resources:
Abstract
3210 - Protein tyrosine phosphatase non-receptor type 3 (PTPN3) could be a new therapeutic target for pancreatic cancer.
Presenter: Akio Yamasaki
Session: Poster Display session 1
Resources:
Abstract
3920 - A Novel bispecific BCMAxCD3 T cell engaging antibody that treat multiple myeloma (MM) with minimal cytokine serection
Presenter: Zhenyu Li
Session: Poster Display session 1
Resources:
Abstract
2691 - Quantitative spatial profiling of lymphocyte-activation gene 3 (LAG-3)/major histocompatibility complex class II (MHC II) interaction in gastric and urothelial tumors
Presenter: Cyrus Hedvat
Session: Poster Display session 1
Resources:
Abstract